J Cosmet Dermatol:皮下分离术联合透明质酸或聚乳酸线可更好的改善痤疮疤痕

2022-08-15 MedSci原创 MedSci原创

痤疮疤痕是皮肤科医生在日常工作中面临的一个非常常见的皮肤问题,也是造成患者社会心理困扰的最常见的美容问题之一。

痤疮疤痕是皮肤科医生在日常工作中面临的一个非常常见的皮肤问题,也是造成患者社会心理困扰的最常见的美容问题之一。研究表明,痤疮疤痕可能是由多种因素的相互作用造成的,包括炎症、细胞外基质的降解和异常肉芽组织的形成。皮下分离术是最常见的治疗技术之一,是采用斜面的皮下注射针进入疤痕组织下,切断纤维带,它可以对萎缩性痤疮瘢痕产生良好的效果,无论是单独使用还是与其他方式结合使用。近日,发表于J Cosmet Dermatol的一项研究评估皮下分离术与交联透明质酸(HA)或聚乳酸(PLLA)线结合治疗萎缩性痤疮后疤痕的疗效。

共有40名萎缩性痤疮疤痕的男女患者接受了皮下分离术,间隔1个月,共3次。在最后一次亚切术后,患者被重新随机分为2组,每组在一侧脸部接受HA或线的治疗,另一侧脸部接受皮下分离术,作为对照。医生和患者进行了临床评估。获得照片和皮肤活检。随访时间为6个月。

结果显示,67.3%的患者在仅接受皮下分离术后取得了明显的临床改善,而在皮下分离术与HA或PLLA线结合的情况下,则分别有94.1%和82.4%的患者取得了明显的临床改善。与单独的皮下分离术相比,联合组的患者满意度更高(P < 0.0001)。联合治疗组的副作用是可容忍的和短暂的。

综上所述,该研究结果表明,与单独的皮下分离术相比,皮下分离术联合HA或PLLA线可以提供更高的痤疮疤痕的明显临床改善。

原始出处:

Howyda M Ebrahim, et al., A combined approach of subcision with either cross-linked hyaluronic acid or threads in the treatment of atrophic acne scars. J Cosmet Dermatol. 2022 Aug;21(8):3334-3342. doi: 10.1111/jocd.14675.  

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1897051, encodeId=d9bf189e05138, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Sep 29 09:51:41 CST 2022, time=2022-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783646, encodeId=36351e8364612, content=<a href='/topic/show?id=f6c9511ec2' target=_blank style='color:#2F92EE;'>#CoSM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5117, encryptionId=f6c9511ec2, topicName=CoSM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Sat Feb 18 08:51:41 CST 2023, time=2023-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276762, encodeId=6fe012e676266, content=<a href='/topic/show?id=ec9e9482383' target=_blank style='color:#2F92EE;'>#透明质酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94823, encryptionId=ec9e9482383, topicName=透明质酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Tue Aug 16 13:51:41 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394141, encodeId=9b211394141b1, content=<a href='/topic/show?id=7b29e0460b1' target=_blank style='color:#2F92EE;'>#疤痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70460, encryptionId=7b29e0460b1, topicName=疤痕)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Tue Aug 16 13:51:41 CST 2022, time=2022-08-16, status=1, ipAttribution=)]
    2022-09-29 一闲
  2. [GetPortalCommentsPageByObjectIdResponse(id=1897051, encodeId=d9bf189e05138, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Sep 29 09:51:41 CST 2022, time=2022-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783646, encodeId=36351e8364612, content=<a href='/topic/show?id=f6c9511ec2' target=_blank style='color:#2F92EE;'>#CoSM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5117, encryptionId=f6c9511ec2, topicName=CoSM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Sat Feb 18 08:51:41 CST 2023, time=2023-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276762, encodeId=6fe012e676266, content=<a href='/topic/show?id=ec9e9482383' target=_blank style='color:#2F92EE;'>#透明质酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94823, encryptionId=ec9e9482383, topicName=透明质酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Tue Aug 16 13:51:41 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394141, encodeId=9b211394141b1, content=<a href='/topic/show?id=7b29e0460b1' target=_blank style='color:#2F92EE;'>#疤痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70460, encryptionId=7b29e0460b1, topicName=疤痕)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Tue Aug 16 13:51:41 CST 2022, time=2022-08-16, status=1, ipAttribution=)]
    2023-02-18 tcm99hq
  3. [GetPortalCommentsPageByObjectIdResponse(id=1897051, encodeId=d9bf189e05138, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Sep 29 09:51:41 CST 2022, time=2022-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783646, encodeId=36351e8364612, content=<a href='/topic/show?id=f6c9511ec2' target=_blank style='color:#2F92EE;'>#CoSM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5117, encryptionId=f6c9511ec2, topicName=CoSM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Sat Feb 18 08:51:41 CST 2023, time=2023-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276762, encodeId=6fe012e676266, content=<a href='/topic/show?id=ec9e9482383' target=_blank style='color:#2F92EE;'>#透明质酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94823, encryptionId=ec9e9482383, topicName=透明质酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Tue Aug 16 13:51:41 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394141, encodeId=9b211394141b1, content=<a href='/topic/show?id=7b29e0460b1' target=_blank style='color:#2F92EE;'>#疤痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70460, encryptionId=7b29e0460b1, topicName=疤痕)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Tue Aug 16 13:51:41 CST 2022, time=2022-08-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1897051, encodeId=d9bf189e05138, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Sep 29 09:51:41 CST 2022, time=2022-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783646, encodeId=36351e8364612, content=<a href='/topic/show?id=f6c9511ec2' target=_blank style='color:#2F92EE;'>#CoSM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5117, encryptionId=f6c9511ec2, topicName=CoSM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Sat Feb 18 08:51:41 CST 2023, time=2023-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276762, encodeId=6fe012e676266, content=<a href='/topic/show?id=ec9e9482383' target=_blank style='color:#2F92EE;'>#透明质酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94823, encryptionId=ec9e9482383, topicName=透明质酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Tue Aug 16 13:51:41 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394141, encodeId=9b211394141b1, content=<a href='/topic/show?id=7b29e0460b1' target=_blank style='color:#2F92EE;'>#疤痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70460, encryptionId=7b29e0460b1, topicName=疤痕)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Tue Aug 16 13:51:41 CST 2022, time=2022-08-16, status=1, ipAttribution=)]
    2022-08-16 HinsMax

相关资讯

Acta Biomater:米诺地尔-透明质酸-溶解微针减轻脱发动物模型的脱发研究

本研究表明透明质酸减少了脱发小鼠的脱发,使用米诺地尔-透明质酸-微针输送米诺地尔和透明质酸可以最大限度地发挥疗效,并将米诺地尔治疗脱发的副作用降至最低。

医美前沿解读:Skinbooster韩国研究-改善皮肤质量的证据

透明质酸,不仅用于软组织填充,也用于改善皮肤质量。

透明质酸填充剂出现并发症怎么办?透明质酸酶来帮忙!

透明质酸填充剂出现并发症怎么办?透明质酸酶来帮忙!

PRP三部曲:PRP嫩肤注射后,全脸皮肤肉瘤样肉芽肿一例

日本医生Naotaka Serizawa等报告的首例通过肺部、眼部和皮肤病变诊断的结节病,表现为面部多发性结节病样肉芽肿,而该患者曾注射PRP治疗皮肤皱纹。

关于在亚洲患者中使用基于透明质酸的填充剂进行非手术隆鼻的共识建议

与传统手术相比,使用透明质酸等真皮填充物的非手术隆鼻术因其创伤小、等待时间短而越来越受欢迎。然而,由于鼻血管系统的复杂性,在没有适当训练的情况下,这是一种高风险的手术。

Support Care Cancer:透明质酸可有效缓解放疗引起的皮肤粘膜副作用

放疗(RT)癌症患者常用的辅助治疗方法,但是RT引起的皮肤粘膜副作用仍然是困扰癌症患者治疗的一大挑战。透明质酸(HA)皮肤细胞外基质的主要成分,也是组织再生的一个关键分子,可以缓解这些副作用。